Galmed Pharmaceuticals Ltd.
GLMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GLMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GLMD
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing Aramchol for oncological indications and expanding its pipeline into cardiometabolic diseases, with no approved products and a history of operating losses.
Key risk: Dependence on Aramchol
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 7 clinical trials · 1 catalyst for Galmed Pharmaceuticals Ltd..
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing Aramchol for oncological indications and expanding its pipeline into cardiometabolic diseases, with no approved products and a history of operating losses.
- Galmed has no approved products and has not generated revenue from product sales, relying on licensing revenue from the Samil Agreement [sec · filed 2026-03-31].
- As of December 31, 2025, the company reported cash and equivalents of $4.0M, shareholders' equity of $16.3M, and a net loss of -$4.8M [sec].
- The company expects its existing funds to support operations for more than 12 months from July 2026, but significant additional funding will be needed for R&D and commercialization [sec · filed 2026-07-08].
- Galmed is actively pursuing opportunities to expand its pipeline into cardiometabolic indications and other innovative product candidates [sec · filed 2026-03-31].
- The company's lead candidate, Aramchol, is being developed for oncological indications outside of NASH and fibrosis, but regulatory approval is uncertain [sec · filed 2026-03-31].
What works
- The company has sufficient cash runway for more than 12 months as of July 2026, providing near-term operational stability [sec · filed 2026-07-08].
- Galmed is actively diversifying its pipeline into cardiometabolic indications, which may reduce reliance on a single candidate [sec · filed 2026-03-31].
- The company has experience in clinical-stage drug development and has secured licensing revenue through the Samil Agreement [sec · filed 2026-03-31].
What to weigh
- Galmed has a history of operating losses and expects to incur significant additional losses, with no guarantee of future profitability [sec · filed 2026-03-31].
- The company depends largely on the success of Aramchol, which has not yet received regulatory approval and faces uncertain clinical trial outcomes [sec · filed 2026-03-31].
- Significant additional funding will be required to advance product candidates through regulatory approval and commercialization, and there is no assurance of obtaining such funding [sec · filed 2026-07-08].
- The company has not yet demonstrated an ability to commercialize any product, and even if approved, products may not gain market acceptance [sec · filed 2026-03-31].
From the filings
Quoted directly from source documents.
The company has no approved products and has not generated revenue from product sales.
“To date, we have not generated revenue from the sale of any product, excluding the licensing revenue we recorded in connection with the Samil Agreement”
SEC filings · March 31, 2026
Galmed expects its existing funds to support operations for more than 12 months from July 2026.
“we believe that our existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months from the date of issuance of this Report on Form 6-K”
SEC filings · July 8, 2026
The company depends largely on the success of Aramchol.
“We depend largely on the success of our lead product candidate, Aramchol, and we may not obtain regulatory approval of Aramchol.”
SEC filings · March 31, 2026
Galmed has a history of operating losses.
“We are a biopharmaceutical company with a history of operating losses. We expect to incur significant additional losses in the future and may never be profitable.”
SEC filings · March 31, 2026
Catalyst timeline
- 2027-06-30 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study t — Topline results from the Phase 3 study of Aramchol will be a key determinant of the drug's regulatory and commercial prospects.
Risks & what to watch (4)›
Key risks
- Dependence on Aramchol — Company depends largely on Aramchol, which may not obtain regulatory approval [sec · filed 2026-03-31].
- Need for additional funding — Significant additional funding required for R&D and commercialization; no assurance of obtaining it [sec · filed 2026-07-08].
- History of operating losses — Company has history of losses and may never achieve profitability [sec · filed 2026-03-31].
- Uncertain clinical trial outcomes — Clinical trial results may be unsatisfactory, and regulatory authorities may not grant approval [sec · filed 2026-03-31].
What to watch
- Phase 3 topline data for Aramchol expected on June 30, 2027 [catalyst_timeline].
- Ability to secure additional funding through debt, equity, or partnerships [sec · filed 2026-07-08].
- Progress in expanding pipeline into cardiometabolic indications [sec · filed 2026-03-31].
- Regulatory developments regarding Aramchol for oncological indications [sec · filed 2026-03-31].
Sources: SEC filings · Generated August 30, 2026 · How we verify sources →
Run Galmed Pharmaceuticals Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Galmed Pharmaceuticals Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.18
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~304d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$70K
| Holder | Shares | Value |
|---|---|---|
| two sigma investments, lp | 80,177 | $39K |
| xtx topco ltd | 22,396 | $11K |
| jane street group, llc | 16,445 | $8K |
| two sigma securities, llc | 11,971 | $6K |
| citadel advisors llc | 11,382 | $6K |
| bnp paribas financial markets | 600 | $294 |
| morgan stanley | 157 | $77 |
| wells fargo & company/mn | 43 | $21 |
| sbi securities co., ltd. | 16 | $8 |
| federation des caisses desjardins du quebec | 14 | $7 |
Showing top 10 of 15 institutional holders of Galmed Pharmaceuticals Ltd.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 7.8%
- Days to cover
- 0.1
- Shares short
- 502,390
- Daily short volume (Aug 14, 2026)
- 21.3%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GLMD short interestFrequently asked questions
What is the AI investment thesis for Galmed Pharmaceuticals Ltd.?
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing Aramchol for oncological indications and expanding its pipeline into cardiometabolic diseases, with no approved products and a history of operating losses.
What is Galmed Pharmaceuticals Ltd.'s next catalyst?
Galmed Pharmaceuticals Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study t" — expected June 30, 2027.
Who is the CEO of Galmed Pharmaceuticals Ltd.?
Mr. Allen Baharaff is the chief executive officer of Galmed Pharmaceuticals Ltd. (GLMD).
Where is Galmed Pharmaceuticals Ltd. headquartered?
Galmed Pharmaceuticals Ltd. (GLMD) is headquartered in Ramat Gan, Israel.
What therapeutic areas does Galmed Pharmaceuticals Ltd. focus on?
Galmed Pharmaceuticals Ltd. develops therapies across Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.